TP53 hotspot in HGSOC — near-universal disease feature; not directly targeted. Hotspot R1...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-R175H-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | R175H |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIA |
| Recommended combinations | bevacizumab + carbo/pacli, PARPi maintenance per HRD/BRCA |
| Evidence summary | TP53 hotspot in HGSOC — near-universal disease feature; not directly targeted. Hotspot R175H is among the most frequent DBD missense — gain-of-function dominant-negative behavior in some functional assays. |
Notes
ESCAT IIIA. Hotspot R175H listed under BIO-TP53-MUTATION (gene-level BIO; no per-hotspot BIO entity).
Used By
No reverse references found in the YAML corpus.